Christopher M. Counter
Professor of Pharmacology and Cancer Biology
The Counter lab studies the molecular mechanisms underlying the evolution of normal cells into cancer. The lab is divided into two major areas studying key features of human cancers.
Immortalization: We have shown that the ability of cancer cells to keep dividing, or become immortal, is a fundamental aspect of tumorigenesis, and is due to elongation of telomeres. Current efforts focus on the molecular biology of telomere-binding proteins in regulating telomere length.
Proliferation: The ability of tumor cells to proliferate inappropriately is a hallmark of cancer. One gene that plays a key role in this process is the oncogene Ras. We have shown that Ras exerts its oncogenic signals through different proteins at different phases of cancer. Current studies focus on how these different pathways promote cancer and how to inhibit their activity.
Immortalization: We have shown that the ability of cancer cells to keep dividing, or become immortal, is a fundamental aspect of tumorigenesis, and is due to elongation of telomeres. Current efforts focus on the molecular biology of telomere-binding proteins in regulating telomere length.
Proliferation: The ability of tumor cells to proliferate inappropriately is a hallmark of cancer. One gene that plays a key role in this process is the oncogene Ras. We have shown that Ras exerts its oncogenic signals through different proteins at different phases of cancer. Current studies focus on how these different pathways promote cancer and how to inhibit their activity.
Current Appointments & Affiliations
- Professor of Pharmacology and Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 2011
- Assistant Professor in Radiation Oncology, Radiation Oncology, Clinical Science Departments 2006
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2002
Contact Information
- C225 Lev Sci Res Ctr, Durham, NC 27708
- Duke Box 3813, Durham, NC 27710
-
count004@mc.duke.edu
(919) 684-9890
- Background
-
Education, Training, & Certifications
- Postdoctoral Fellow, Whitehead Institute For Biomedical Research, Massachusetts Institute of Technology - 1998
- Ph.D., McMaster University 1996
- B.S., McMaster University 1990
-
Duke Appointment History
- Associate Professor of Pharmacology & Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 2005 - 2011
- Assistant Research Professor in Radiation Oncology, Radiation Oncology, Clinical Science Departments 1998 - 2006
- Assistant Professor of Pharmacology & Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 1998 - 2005
- Instructor, Temporary of Pharmacology & Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 1998
- Recognition
-
In the News
-
Awards & Honors
- Research
-
Selected Grants
- Medical Scientist Training Program awarded by National Institutes of Health 1997 - 2022
- The role of NRF2 in breast cancer dormancy and recurrence awarded by National Institutes of Health 2019 - 2021
- Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2021
- Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
- The role of dietary copper in melanoma awarded by National Institutes of Health 2015 - 2020
- Genetics Training Grant awarded by National Institutes of Health 1979 - 2020
- Organization and Function of Cellular Structure awarded by National Institutes of Health 1975 - 2020
- Pharmacological Sciences Training Program awarded by National Institutes of Health 1975 - 2020
- Pharmacology Industry Internships for Ph.D. Students awarded by American Society for Pharmacology and Experimental Therapeutics 2017 - 2019
- Dynamic requirements of Ras signaling during cancer awarded by National Institutes of Health 2014 - 2019
- Thermo Lumos Tribrid High-Resolution Accurate-Mass Tandem Mass Spectrometer awarded by National Institutes of Health 2018 - 2019
- Identification and validation of the PAX3-FOXO1 protein interactome awarded by St. Baldrick's Foundation 2018 - 2019
- Duke University Program in Environmental Health awarded by National Institute of Environmental Health Sciences 2013 - 2019
- Viral Oncology Training Grant awarded by National Institutes of Health 1980 - 2019
- Defining RAS isoform- and mutation-specific roles in oncogenesis awarded by University of North Carolina - Chapel Hill 2016 - 2019
- Defining RAS isoform- and mutation-specific roles in oncogenesis awarded by University of North Carolina - Chapel Hill 2016 - 2019
- Defining RAS isoform- and mutation-specific roles in oncogenesis awarded by University of North Carolina - Chapel Hill 2016 - 2019
- RalA signal transduction awarded by National Institutes of Health 2002 - 2019
- Elucidating the Role of Kras Specificity Determinants in Pancreatic Cancer awarded by Pancreatic Cancer Action Network 2017 - 2018
- Leveraging copper chelation as targeted therapy for BRAF-driven thyroid cancer awarded by Triangle Community Foundation 2015 - 2018
- Center for Molecular & Cellular Studies of Ped Disease awarded by National Institutes of Health 2003 - 2018
- The role of KRAS codon bias in tumorigenesis awarded by National Institutes of Health 2016 - 2017
- The effect of oncogenic Ras signaling strength on cancer awarded by National Institutes of Health 2013 - 2017
- A Platform for Real-time Drug Profiling of Patient-Derived Melanomas awarded by National Institutes of Health 2014 - 2016
- Cancer Biology Training Grant awarded by National Cancer Institute 1993 - 2016
- Examining infection-mediated metastasis with single-cell resolution awarded by National Institutes of Health 2014 - 2016
- Pleiotrophin, a paracrine regulator of hematopoietic stem cell fate awarded by University of California - Los Angeles 2014 - 2015
- Copper reduction as a novel therapy in BRAF-mutant positive cancers awarded by National Institutes of Health 2013 - 2015
- Reducing dietary copper for the treatment of BRaf mutation-positive melanoma awarded by National Institutes of Health 2013 - 2015
- JUN PROTEINS IN EPIDERMAL HOMEOSTASIS AND NEOPLASIA awarded by National Institutes of Health 2010 - 2015
- Instrumentation for Quantitative Phosphoproteomics and Acetylomics awarded by National Institutes of Health 2014 - 2015
- Evaluating the impact of KRas codon bias on pancreatic cancer awarded by National Institutes of Health 2012 - 2014
- The role of RalA in pancreatic tumorigenesis awarded by National Institutes of Health 2008 - 2013
- Small molecular weight eNOS inhibitors for the treatment of pancreatic cancer awarded by National Institutes of Health 2011 - 2013
- Preclinical evaluation of NOS inhibitors for the treatment of pancreatic cancer awarded by National Institutes of Health 2009 - 2011
- NF-kB, CDK4 and JNK in Epidermal Growth Regulation awarded by National Institutes of Health 2005 - 2010
- The Molecular Basis of Telomerase Function & Regulation awarded by National Institutes of Health 1999 - 2009
- Developing inhibitors of RalA function for the treatment of pancreatic cancer awarded by National Institutes of Health 2007 - 2009
- Targeting Functional Domains in Telomerase awarded by National Institutes of Health 2002 - 2004
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Li, Siqi, Allan Balmain, and Christopher M. Counter. “A model for RAS mutation patterns in cancers: finding the sweet spot..” Nature Reviews. Cancer 18, no. 12 (December 2018): 767–77. https://doi.org/10.1038/s41568-018-0076-6.Full Text
-
Fu, Jingjing, Yunkun Dang, Christopher Counter, and Yi Liu. “Codon usage regulates human KRAS expression at both transcriptional and translational levels..” The Journal of Biological Chemistry 293, no. 46 (November 2018): 17929–40. https://doi.org/10.1074/jbc.ra118.004908.Full Text
-
Adhikari, Hema, and Christopher M. Counter. “Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability..” Nature Communications 9, no. 1 (September 7, 2018). https://doi.org/10.1038/s41467-018-05692-6.Full Text
-
Xu, MengMeng, Michael Casio, Danielle E. Range, Julie A. Sosa, and Christopher M. Counter. “Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24, no. 17 (September 2018): 4271–81. https://doi.org/10.1158/1078-0432.ccr-17-3705.Full Text
-
Kabiri, Zahra, Gediminas Greicius, Hamed Zaribafzadeh, Amanda Hemmerich, Christopher M. Counter, and David M. Virshup. “Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells..” The Journal of Clinical Investigation 128, no. 9 (August 2018): 3806–12. https://doi.org/10.1172/JCI99325.Full Text
-
Sasine, Joshua P., Heather A. Himburg, Christina M. Termini, Martina Roos, Evelyn Tran, Liman Zhao, Jenny Kan, et al. “Wild-type Kras expands and exhausts hematopoietic stem cells..” Jci Insight 3, no. 11 (June 7, 2018). https://doi.org/10.1172/jci.insight.98197.Full Text
-
Brady, Donita C., Matthew S. Crowe, Danielle N. Greenberg, and Christopher M. Counter. “Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors..” Cancer Research 77, no. 22 (November 2017): 6240–52. https://doi.org/10.1158/0008-5472.CAN-16-1190.Full Text
-
Anderson, Grace R., Peter S. Winter, Kevin H. Lin, Daniel P. Nussbaum, Merve Cakir, Elizabeth M. Stein, Ryan S. Soderquist, et al. “A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution..” Cell Reports 20, no. 4 (July 2017): 999–1015. https://doi.org/10.1016/j.celrep.2017.07.006.Full Text
-
Ali, Moiez, Erin Kaltenbrun, Grace R. Anderson, Sarah Jo Stephens, Sabrina Arena, Alberto Bardelli, Christopher M. Counter, and Kris C. Wood. “Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance..” Nat Commun 8 (June 8, 2017). https://doi.org/10.1038/ncomms15617.Full Text Link to Item
-
Pershing, Nicole L. K., Chi-Fu Jeffrey Yang, MengMeng Xu, and Christopher M. Counter. “Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer..” Oncotarget 7, no. 27 (July 2016): 42385–92. https://doi.org/10.18632/oncotarget.9874.Full Text
-
Weyandt, Jamie D., John M. Carney, Elizabeth N. Pavlisko, MengMeng Xu, and Christopher M. Counter. “Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice..” Plos One 11, no. 12 (January 2016). https://doi.org/10.1371/journal.pone.0167205.Full Text
-
Counter, Chris. “Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis..” Redox Biology 5 (August 2015). https://doi.org/10.1016/j.redox.2015.09.023.Full Text
-
Kashatus, Jennifer A., Aldo Nascimento, Lindsey J. Myers, Annie Sher, Frances L. Byrne, Kyle L. Hoehn, Christopher M. Counter, and David F. Kashatus. “Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth..” Molecular Cell 57, no. 3 (February 2015): 537–51. https://doi.org/10.1016/j.molcel.2015.01.002.Full Text
-
Petersen, T. H., T. Hitchcock, A. Muto, E. A. Calle, L. Zhao, Z. Gong, L. Gui, et al. “Utility of telomerase-potl fusion protein in vascular tissue engineering.” Cell Transplantation 19, no. 1 (April 14, 2010): 78–87. https://doi.org/10.3727/096368909X478650.Full Text
-
Issaq, Sameer H., Kian-Huat Lim, and Christopher M. Counter. “Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis..” Molecular Cancer Research : Mcr 8, no. 2 (February 9, 2010): 223–31. https://doi.org/10.1158/1541-7786.MCR-09-0189.Full Text
-
Lim, Kian-Huat, Donita C. Brady, David F. Kashatus, Brooke B. Ancrile, Channing J. Der, Adrienne D. Cox, and Christopher M. Counter. “Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA..” Molecular and Cellular Biology 30, no. 2 (January 2010): 508–23. https://doi.org/10.1128/MCB.00916-08.Full Text
-
Petersen, T. H., T. Hitchcock, A. Muto, E. A. Calle, L. Zhao, Z. Gong, L. Gui, et al. “Utility of telomerase-pot1 fusion protein in vascular tissue engineering..” Cell Transplantation 19, no. 1 (2010): 79–87. https://doi.org/10.3727/096368909X478650.Full Text
-
Petersen, Thomas H., Thomas Hitchcock, Akihito Muto, Elizabeth A. Calle, Liping Zhao, Zhaodi Gong, Liqiong Gui, et al. “Utility of telomerase-pot1 fusion protein in vascular tissue engineering..” Cell Transplantation 19, no. 1 (January 2010): 79–87. https://doi.org/10.3727/096368909X478650.Full Text Open Access Copy
-
O’Hayer, Kevin M., Donita C. Brady, and Christopher M. Counter. “ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis..” Carcinogenesis 30, no. 11 (November 2009): 1841–47. https://doi.org/10.1093/carcin/bgp198.Full Text
-
Kendellen, Megan F., Katharine S. Barrientos, and Christopher M. Counter. “POT1 association with TRF2 regulates telomere length..” Molecular and Cellular Biology 29, no. 20 (October 2009): 5611–19. https://doi.org/10.1128/MCB.00286-09.Full Text
-
Naini, Sarasija, Katherine T. Etheridge, Stacey J. Adam, Stephen J. Qualman, Rex C. Bentley, Christopher M. Counter, and Corinne M. Linardic. “Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma..” Cancer Res 68, no. 23 (December 1, 2008): 9583–88. https://doi.org/10.1158/0008-5472.CAN-07-6178.Full Text Link to Item
-
Lee, Yi-Shan, Kian-Huat Lim, Xing Guo, Yoshiharu Kawaguchi, Yasheng Gao, Tomasa Barrientos, Peter Ordentlich, Xiao-Fan Wang, Christopher M. Counter, and Tso-Pang Yao. “The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.” Cancer Research 68, no. 18 (September 15, 2008): 7561–69. https://doi.org/10.1159/0008-5472.CAN-08-0188.Full Text Link to Item
-
Barrientos, Katharine S., Megan F. Kendellen, Brian D. Freibaum, Blaine N. Armbruster, Katherine T. Etheridge, and Christopher M. Counter. “Distinct functions of POT1 at telomeres..” Molecular and Cellular Biology 28, no. 17 (September 2008): 5251–64. https://doi.org/10.1128/MCB.00048-08.Full Text
-
Lee, Yi-Shan, Kian-Huat Lim, Xing Guo, Yoshiharu Kawaguchi, Yasheng Gao, Tomasa Barrientos, Peter Ordentlich, Xiao-Fan Wang, Christopher M. Counter, and Tso-Pang Yao. “The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis..” Cancer Research 68, no. 18 (September 2008): 7561–69. https://doi.org/10.1158/0008-5472.CAN-08-0188.Full Text
-
Tomlinson, Rebecca L., Eladio B. Abreu, Tania Ziegler, Hinh Ly, Christopher M. Counter, Rebecca M. Terns, and Michael P. Terns. “Telomerase reverse transcriptase is required for the localization of telomerase RNA to cajal bodies and telomeres in human cancer cells..” Molecular Biology of the Cell 19, no. 9 (September 2008): 3793–3800. https://doi.org/10.1091/mbc.E08-02-0184.Full Text
-
Freibaum, Brian D., and Christopher M. Counter. “The protein hSnm1B is stabilized when bound to the telomere-binding protein TRF2..” J Biol Chem 283, no. 35 (August 29, 2008): 23671–76. https://doi.org/10.1074/jbc.M800388200.Full Text Link to Item
-
Lim, Kian-Huat, Brooke B. Ancrile, David F. Kashatus, and Christopher M. Counter. “Tumour maintenance is mediated by eNOS..” Nature 452, no. 7187 (April 2008): 646–49. https://doi.org/10.1038/nature06778.Full Text
-
Etheridge, Katherine T., Sarah A. Compton, Katharine S. Barrientos, Sezgin Ozgur, Jack D. Griffith, and Christopher M. Counter. “Tethering telomeric double- and single-stranded DNA-binding proteins inhibits telomere elongation..” J Biol Chem 283, no. 11 (March 14, 2008): 6935–41. https://doi.org/10.1074/jbc.M708711200.Full Text Link to Item
-
Ancrile, Brooke B., Kevin M. O’Hayer, and Christopher M. Counter. “Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics..” Molecular Interventions 8, no. 1 (February 2008): 22–27. https://doi.org/10.1124/mi.8.1.6.Full Text
-
Adam, Stacey J., and Christopher M. Counter. “A method to generate genetically defined tumors in pigs..” Methods in Enzymology 439 (January 2008): 39–51. https://doi.org/10.1016/S0076-6879(07)00404-1.Full Text
-
Linardic, Corinne M., and Christopher M. Counter. “Genetic modeling of Ras-induced human rhabdomyosarcoma..” Methods in Enzymology 438 (January 2008): 419–27. https://doi.org/10.1016/S0076-6879(07)38028-2.Full Text
-
Schook, L. B., K. Kuzmuk, S. Adam, L. Rund, K. Chen, M. Rogatcheva, M. Mazur, C. Pollock, and C. Counter. “DNA-based animal models of human disease: from genotype to phenotype..” Developments in Biologicals 132 (January 2008): 15–25. https://doi.org/10.1159/000317140.Full Text
-
Banik, S. S. R., and C. M. Counter. “From bread to bedside: What budding yeast has taught us about the immortalization of cancer cells,” December 1, 2007, 123–39. https://doi.org/10.1007/978-1-4020-5963-6_5.Full Text
-
Rogatcheva, Margarita B., Krista L. Fritz, Laurie A. Rund, Callie B. Pollock, Jonathan E. Beever, Christopher M. Counter, and Lawrence B. Schook. “Characterization of the porcine ATM gene: towards the generation of a novel non-murine animal model for Ataxia-Telangiectasia..” Gene 405, no. 1–2 (December 2007): 27–35. https://doi.org/10.1016/j.gene.2007.08.014.Full Text
-
Ancrile, Brooke, Kian-Huat Lim, and Christopher M. Counter. “Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis..” Genes & Development 21, no. 14 (July 2007): 1714–19. https://doi.org/10.1101/gad.1549407.Full Text
-
Linardic, Corinne M., Sarasija Naini, James E. Herndon, Chimen Kesserwan, Stephen J. Qualman, and Christopher M. Counter. “The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence..” Cancer Research 67, no. 14 (July 2007): 6691–99. https://doi.org/10.1158/0008-5472.can-06-3210.Full Text
-
Adam, S. J., L. A. Rund, K. N. Kuzmuk, J. F. Zachary, L. B. Schook, and C. M. Counter. “Genetic induction of tumorigenesis in swine..” Oncogene 26, no. 7 (February 2007): 1038–45. https://doi.org/10.1038/sj.onc.1209892.Full Text
-
Lim, Kian-Huat, Kevin O’Hayer, Stacey J. Adam, S Disean Kendall, Paul M. Campbell, Channing J. Der, and Christopher M. Counter. “Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells..” Current Biology : Cb 16, no. 24 (December 2006): 2385–94. https://doi.org/10.1016/j.cub.2006.10.023.Full Text
-
Freibaum, Brian D., and Christopher M. Counter. “hSnm1B is a novel telomere-associated protein..” J Biol Chem 281, no. 22 (June 2, 2006): 15033–36. https://doi.org/10.1074/jbc.C600038200.Full Text Link to Item
-
Kendall, S DiSean, Stacey J. Adam, and Christopher M. Counter. “Genetically engineered human cancer models utilizing mammalian transgene expression..” Cell Cycle (Georgetown, Tex.) 5, no. 10 (May 15, 2006): 1074–79. https://doi.org/10.4161/cc.5.10.2734.Full Text
-
Baines, Antonio T., Kian-Huat Lim, Janiel M. Shields, John M. Lambert, Christopher M. Counter, Channing J. Der, and Adrienne D. Cox. “Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth..” Methods in Enzymology 407 (January 2006): 556–74. https://doi.org/10.1016/s0076-6879(05)07045-x.Full Text
-
O’Hayer, Kevin M., and Christopher M. Counter. “A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro..” Methods in Enzymology 407 (January 2006): 637–47. https://doi.org/10.1016/s0076-6879(05)07050-3.Full Text
-
Kendall, S DiSean, Corinne M. Linardic, Stacey J. Adam, and Christopher M. Counter. “A network of genetic events sufficient to convert normal human cells to a tumorigenic state..” Cancer Research 65, no. 21 (November 2005): 9824–28. https://doi.org/10.1158/0008-5472.can-05-1543.Full Text
-
Lim, K. H., and C. M. Counter. “Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.” Cancer Cell 8, no. 5 (November 2005): 381–92. https://doi.org/10.1016/j.ccr.2005.10.014.Full Text Link to Item
-
Lim, Kian-Huat, and Christopher M. Counter. “Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance..” Cancer Cell 8, no. 5 (November 2005): 381–92. https://doi.org/10.1016/j.ccr.2005.10.014.Full Text
-
Kassem, Moustapha, Jorge Burns, and Basem Abd-Allah. “Blood vessels engineered from human cells..” Lancet (London, England) 366, no. 9489 (September 2005): 891–92. https://doi.org/10.1016/s0140-6736(05)67311-4.Full Text
-
Lim, Kian-Huat, Antonio T. Baines, James J. Fiordalisi, Michail Shipitsin, Larry A. Feig, Adrienne D. Cox, Channing J. Der, and Christopher M. Counter. “Activation of RalA is critical for Ras-induced tumorigenesis of human cells..” Cancer Cell 7, no. 6 (June 2005): 533–45. https://doi.org/10.1016/j.ccr.2005.04.030.Full Text
-
Linardic, Corinne M., Diane L. Downie, Stephen Qualman, Rex C. Bentley, and Christopher M. Counter. “Genetic modeling of human rhabdomyosarcoma..” Cancer Res 65, no. 11 (June 1, 2005): 4490–95. https://doi.org/10.1158/0008-5472.CAN-04-3194.Full Text Link to Item
-
Poh, Melissa, Matthew Boyer, Amy Solan, Shannon L. M. Dahl, Dawn Pedrotty, Soma S. R. Banik, J Andrew McKee, Rebecca Y. Klinger, Christopher M. Counter, and Laura E. Niklason. “Blood vessels engineered from human cells..” Lancet (London, England) 365, no. 9477 (June 2005): 2122–24. https://doi.org/10.1016/s0140-6736(05)66735-9.Full Text
-
Banik, Soma S. R., and Christopher M. Counter. “Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR..” J Biol Chem 279, no. 50 (December 10, 2004): 51745–48. https://doi.org/10.1074/jbc.M408131200.Full Text Link to Item
-
Veldman, Timothy, Katherine T. Etheridge, and Christopher M. Counter. “Loss of hPot1 function leads to telomere instability and a cut-like phenotype..” Current Biology : Cb 14, no. 24 (December 2004): 2264–70. https://doi.org/10.1016/j.cub.2004.12.031.Full Text
-
Swanson, Kelly S., Meredith J. Mazur, Kapil Vashisht, Laurie A. Rund, Jonathan E. Beever, Christopher M. Counter, and Lawrence B. Schook. “Genomics and clinical medicine: rationale for creating and effectively evaluating animal models..” Experimental Biology and Medicine (Maywood, N.J.) 229, no. 9 (October 2004): 866–75. https://doi.org/10.1177/153537020422900902.Full Text
-
Lim, Kian-Huat, and Christopher M. Counter. “Leveling the playing field..” Molecular Cell 15, no. 4 (August 2004): 491–92. https://doi.org/10.1016/j.molcel.2004.08.014.Full Text
-
Armbruster, Blaine N., Corinne M. Linardic, Tim Veldman, Niharika P. Bansal, Diane L. Downie, and Christopher M. Counter. “Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1..” Molecular and Cellular Biology 24, no. 8 (April 2004): 3552–61. https://doi.org/10.1128/MCB.24.8.3552-3561.2004.Full Text
-
Yeh, Elizabeth, Melissa Cunningham, Hugh Arnold, Dawn Chasse, Teresa Monteith, Giovanni Ivaldi, William C. Hahn, et al. “A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells..” Nature Cell Biology 6, no. 4 (April 2004): 308–18. https://doi.org/10.1038/ncb1110.Full Text
-
Rogatcheva, Margarita M., Laurie A. Rund, Kelly S. Swanson, Brandy M. Marron, Jonathan E. Beever, Christopher M. Counter, and Lawrence B. Schook. “Creating porcine biomedical models through recombineering..” Comparative and Functional Genomics 5, no. 3 (January 2004): 262–67. https://doi.org/10.1002/cfg.404.Full Text
-
Guo, Chuanhai, Blaine N. Armbruster, David T. Price, and Christopher M. Counter. “In vivo regulation of hTERT expression and telomerase activity by androgen..” The Journal of Urology 170, no. 2 Pt 1 (August 2003): 615–18. https://doi.org/10.1097/01.ju.0000074653.22766.c8.Full Text
-
McKee, J Andrew, Soma S. R. Banik, Matthew J. Boyer, Nesrin M. Hamad, Jeffrey H. Lawson, Laura E. Niklason, and Christopher M. Counter. “Human arteries engineered in vitro..” Embo Reports 4, no. 6 (June 2003): 633–38. https://doi.org/10.1038/sj.embor.embor847.Full Text
-
Armbruster, Blaine N., Katherine T. Etheridge, Dominique Broccoli, and Christopher M. Counter. “Putative telomere-recruiting domain in the catalytic subunit of human telomerase..” Molecular and Cellular Biology 23, no. 9 (May 2003): 3237–46. https://doi.org/10.1128/MCB.23.9.3237-3246.2003.Full Text
-
Rich, Jeremy N., Qing Shi, Mark Hjelmeland, Thomas J. Cummings, Chien-Tsun Kuan, Darell D. Bigner, Christopher M. Counter, and Xiao-Fan Wang. “Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model..” The Journal of Biological Chemistry 278, no. 18 (May 2003): 15951–57. https://doi.org/10.1074/jbc.m211498200.Full Text
-
Counter, Christopher M., William Press, and Carolyn C. Compton. “Telomere shortening in cultured autografts of patients with burns..” Lancet (London, England) 361, no. 9366 (April 2003): 1345–46. https://doi.org/10.1016/s0140-6736(03)13042-5.Full Text
-
Hamad, Nesrin M., Soma S. R. Banik, and Christopher M. Counter. “Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells..” Oncogene 21, no. 46 (October 2002): 7121–25. https://doi.org/10.1038/sj.onc.1205860.Full Text
-
Banik, Soma S. R., Chuanhai Guo, Allyson C. Smith, Seth S. Margolis, D Ashley Richardson, Carlos A. Tirado, and Christopher M. Counter. “C-terminal regions of the human telomerase catalytic subunit essential for in vivo enzyme activity..” Molecular and Cellular Biology 22, no. 17 (September 2002): 6234–46. https://doi.org/10.1128/MCB.22.17.6234-6246.2002.Full Text
-
Hamad, Nesrin M., Joel H. Elconin, Antoine E. Karnoub, Wenli Bai, Jeremy N. Rich, Robert T. Abraham, Channing J. Der, and Christopher M. Counter. “Distinct requirements for Ras oncogenesis in human versus mouse cells..” Genes & Development 16, no. 16 (August 2002): 2045–57. https://doi.org/10.1101/gad.993902.Full Text
-
Etheridge, Katherine T., Soma S. R. Banik, Blaine N. Armbruster, Yusheng Zhu, Rebecca M. Terns, Michael P. Terns, and Christopher M. Counter. “The nucleolar localization domain of the catalytic subunit of human telomerase..” The Journal of Biological Chemistry 277, no. 27 (July 2002): 24764–70. https://doi.org/10.1074/jbc.m201227200.Full Text
-
Shi, Songtao, Stan Gronthos, Shaoqiong Chen, Anand Reddi, Christopher M. Counter, Pamela G. Robey, and Cun-Yu Wang. “Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression..” Nature Biotechnology 20, no. 6 (June 2002): 587–91. https://doi.org/10.1038/nbt0602-587.Full Text
-
Armbruster, B. N., S. S. Banik, C. Guo, A. C. Smith, and C. M. Counter. “N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo..” Molecular and Cellular Biology 21, no. 22 (November 2001): 7775–86. https://doi.org/10.1128/MCB.21.22.7775-7786.2001.Full Text
-
Guo, C., D. Geverd, R. Liao, N. Hamad, C. M. Counter, and D. T. Price. “Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells..” The Journal of Urology 166, no. 2 (August 2001): 694–98. https://doi.org/10.1016/s0022-5347(05)66045-4.Full Text
-
Rich, J. N., C. Guo, R. E. McLendon, D. D. Bigner, X. F. Wang, and C. M. Counter. “A genetically tractable model of human glioma formation..” Cancer Research 61, no. 9 (May 2001): 3556–60.
-
Hu, P. P., X. Shen, D. Huang, Y. Liu, C. Counter, and X. F. Wang. “The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta..” J Biol Chem 274, no. 50 (December 10, 1999): 35381–87. https://doi.org/10.1074/jbc.274.50.35381.Full Text Link to Item
-
Hahn, W. C., C. M. Counter, A. S. Lundberg, R. L. Beijersbergen, M. W. Brooks, and R. A. Weinberg. “Creation of human tumour cells with defined genetic elements..” Nature 400, no. 6743 (July 1999): 464–68. https://doi.org/10.1038/22780.Full Text
-
Xie, Y., C. Counter, and E. Alani. “Characterization of the repeat-tract instability and mutator phenotypes conferred by a Tn3 insertion in RFC1, the large subunit of the yeast clamp loader..” Genetics 151, no. 2 (February 1999): 499–509.
-
Counter, C. M., W. C. Hahn, W. Wei, S. D. Caddle, R. L. Beijersbergen, P. M. Lansdorp, J. M. Sedivy, and R. A. Weinberg. “Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization..” Proceedings of the National Academy of Sciences of the United States of America 95, no. 25 (December 1998): 14723–28. https://doi.org/10.1073/pnas.95.25.14723.Full Text
-
Kolquist, K. A., L. W. Ellisen, C. M. Counter, M. Meyerson, L. K. Tan, R. A. Weinberg, D. A. Haber, and W. L. Gerald. “Expression of TERT in early premalignant lesions and a subset of cells in normal tissues..” Nature Genetics 19, no. 2 (June 1998): 182–86. https://doi.org/10.1038/554.Full Text
-
Counter, C. M., M. Meyerson, E. N. Eaton, L. W. Ellisen, S. D. Caddle, D. A. Haber, and R. A. Weinberg. “Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase..” Oncogene 16, no. 9 (March 1998): 1217–22. https://doi.org/10.1038/sj.onc.1201882.Full Text
-
Counter, C. M., M. Meyerson, E. N. Eaton, and R. A. Weinberg. “The catalytic subunit of yeast telomerase..” Proceedings of the National Academy of Sciences of the United States of America 94, no. 17 (August 1997): 9202–7. https://doi.org/10.1073/pnas.94.17.9202.Full Text
-
Meyerson, M., C. M. Counter, E. N. Eaton, L. W. Ellisen, P. Steiner, S. D. Caddle, L. Ziaugra, et al. “hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization..” Cell 90, no. 4 (August 1997): 785–95. https://doi.org/10.1016/s0092-8674(00)80538-3.Full Text
-
Counter, C. M. “The roles of telomeres and telomerase in cell life span..” Mutation Research 366, no. 1 (October 1996): 45–63.
-
Bacchetti, S., and C. Counter. “Telomeres and telomerase in human cancer (review)..” International Journal of Oncology 7, no. 3 (September 1995): 423–32.
-
Counter, C. M., J. Gupta, C. B. Harley, B. Leber, and S. Bacchetti. “Telomerase activity in normal leukocytes and in hematologic malignancies..” Blood 85, no. 9 (May 1995): 2315–20.
-
Counter, C. M., F. M. Botelho, P. Wang, C. B. Harley, and S. Bacchetti. “Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes..” Journal of Virology 68, no. 5 (May 1994): 3410–14.
-
Counter, C. M., H. W. Hirte, S. Bacchetti, and C. B. Harley. “Telomerase activity in human ovarian carcinoma..” Proc Natl Acad Sci U S A 91, no. 8 (April 12, 1994): 2900–2904. https://doi.org/10.1073/pnas.91.8.2900.Full Text Link to Item
-
Harley, C. B., N. W. Kim, K. R. Prowse, S. L. Weinrich, K. S. Hirsch, M. D. West, S. Bacchetti, H. W. Hirte, C. M. Counter, and C. W. Greider. “Telomerase, cell immortality, and cancer..” Cold Spring Harbor Symposia on Quantitative Biology 59 (January 1994): 307–15. https://doi.org/10.1101/sqb.1994.059.01.035.Full Text
-
Harley, C. B., H. Vaziri, C. M. Counter, and R. C. Allsopp. “The telomere hypothesis of cellular aging..” Experimental Gerontology 27, no. 4 (July 1992): 375–82. https://doi.org/10.1016/0531-5565(92)90068-b.Full Text
-
Counter, C. M., A. A. Avilion, C. E. LeFeuvre, N. G. Stewart, C. W. Greider, C. B. Harley, and S. Bacchetti. “Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity..” The Embo Journal 11, no. 5 (May 1992): 1921–29. https://doi.org/10.1002/j.1460-2075.1992.tb05245.x.Full Text
-
-
Conference Papers
-
GREIDER, C. W., C. AUTEXIER, A. A. AVILION, K. COLLINS, L. A. HARRINGTON, L. L. MANTELL, K. R. PROWSE, et al. “TELOMERES AND TELOMERASE - BIOCHEMISTRY AND REGULATION IN SENESCENCE AND IMMORTALIZATION.” In Chromosome, edited by J. S. Heslopharrison and R. B. Flavell, 115–25. BIOS SCIENTIFIC PUBLISHERS LTD, 1993.Link to Item
-
-
- Teaching & Mentoring
-
Recent Courses
- PHARM 393: Research Independent Study 2019
- PHARM 394: Research Independent Study 2019
- PHARM 493: Research Independent Study 2019
- PHARM 494: Research Independent Study 2019
- PHARM 495: Research Independent Study 2018
- MOLCAN 818: Molecular Mechanisms of Oncogenesis 2017
- PHARM 818: Molecular Mechanisms of Oncogenesis 2017
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
